Benzinga | Aug 30, 2021 08:44AM EDT

Catalent Makes Strategic Move For Consumer Health Business With Bettera Deal

* Catalent Inc (NYSE:CTLT) has reported Q4 sales of $1.19 billion, +25% Y/Y as reported, or 22% in constant currency, edging out analysts' average expectation of $1.14 billion.

* Adjusted EPS of $1.16 surpassed the consensus of $1.03.

* Adjusted EBITDA was $348 million, or a margin of 29.3%, compared to $268 million (28.2%) a year ago.

* Biologics segment sales increased 69% (66% cc) to $603 million.

* Softgel and Oral Technologies segment revenues of $301 million were up 3% (-1% cc).

* The Oral and Specialty Delivery segment's sales were $186 million, a decrease of 15% (-19% cc).

* Clinical Supply Services segment revenues improved 25% (21% cc) to $105 million.

* Guidance: For FY22, Catalent expects revenue of $4.30 billion - $4.50 billion, versus the consensus of $4.33 billion.

* It expects adjusted EBITDA of $1.13 billion - $1.20 billion and adjusted net income of $585 million - $650 million.

* Concurrently, Catalent agreed to acquire Bettera Brands from Highlander Partners for $1 billion.

* Bettera manufacturers gummy, soft chew, and lozenge segments of the nutritional supplements market.

* It maintains four manufacturing operations in California, Virginia, New Jersey, and Indiana.

* The transaction is expected to close by the end of 2021.

* Catalent held cash and cash equivalents of $896 million as of June 30, 2021.

* Related Content: Catalent Buys Promethera's Cell Therapy Subsidiary To Scale-Up Plasmid DNA Efforts.

* Price Action: CTLT stock is up 0.06% at $129.85 during the premarket session on the last check Monday.